Semaglutide in Alcohol Use Disorder
A 45-week, Randomized, Controlled Trial of Semaglutide on Alcohol Related Outcomes in Adults With Alcohol Use Disorder and Obesity
This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes (alcohol intake, cravings, self-control, affect, quality of life, physiologic data; collected using validated questionnaires and in one's natural environments using ecological momentary assessment (EMA) and wearable devices [i.e., activity/health trackers]) among 128 adults (18 to 65 years old) with alcohol use disorder (AUD) and obesity (body mass index (BMI) >/= 30). We also seek to develop personal causal models for alcohol use and urges.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Eric Bomberg, MD
- Telefonnummer: (612) 626-2349
- E-post: bombe002@umn.edu
Studiesteder
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55414
- University of Minnesota Center for Pediatric Obesity Medicine
-
Ta kontakt med:
- Eric Bomberg, MD
- Telefonnummer: (612) 626-2349
- E-post: bombe002@umn.edu
-
Hovedetterforsker:
- Eric Bomberg, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18-65 years
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for mild or moderate AUD
- >/=1 bout of heavy drinking (defined as >/= 4 drinks/day for females; >/= 5 drinks/day for males) within the last month
- Have an interest in reducing or quitting alcohol intake
- Have obesity (defined as BMI >/= 30 kg/m2) at screening
- Ability to provide informed consent before any trial-related activities
Exclusion Criteria:
- Impaired ability to provide consent to a clinical trial and/or comply with study procedures and/or measures using a smartphone (e.g., intellectual disability, acute intoxication, etc.)
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for Severe AUD
- Lifetime diagnosis of psychosis and/or bipolar-spectrum disorders
- Serious withdrawal symptoms defined as a score higher than 9 on Clinical Institute Withdrawal Assessment (CIWA) for Alcohol Scale, Revised at the baseline visit
- Current or history of neurological disease including traumatic brain injury
- Diagnosis of type 1 diabetes mellitus
- Diagnosis of type 2 diabetes mellitus with A1c >/= 10% or type 2 diabetes mellitus on insulin therapy
- Current hyperthyroidism or uncontrolled hypothyroidism
- Current pregnancy or breast-feeding, plans to become pregnant within the next 12 months, or if sexually active refusal to use adequate contraceptive measures
- Impaired hepatic function (aspartate aminotransferase (AST)or alanine aminotransferase (ALT) > 3 times upper normal limit
- Impaired renal function (estimated glomerular filtration rate (eGFR)< 50 mL/minute
- Known hypersensitivity to semaglutide
- Any history of pancreatitis (acute or chronic; contraindication for semaglutide)
- Triglycerides >/= 1000 mg/dL
- History of medullary thyroid carcinoma (MTC) and/or family history with MTC and/or multiple endocrine neoplasia syndrome type 2 (contraindication for semaglutide)
- Uncontrolled hypertension (systolic blood pressure > 180 mm Hg; diastolic blood pressure > 110 mm Hg)
- Concomitant pharmacotherapy for alcohol dependence (e.g. disulfiram, naltrexone, acamprosate) or treatment with any of these within 1 month prior to screening visit
- Current or recent (< 6 months prior to screening) use of weight loss medication(s) (e.g., phentermine, Glucagon-Like Peptide-1 Receptor Agonist (GLP1-RAs)) or other weight altering medication(s) (e.g., atypical anti-psychotics), unless dose(s) of these have been stable for >6 months from screening
- Any condition that the investigator feels would interfere with trial participation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: Semaglutide
Participants in this arm of the study will receive semaglutide (the study drug) |
Participants in this arm will receive 42 weeks of treatment with semaglutide |
|
Placebo komparator: Placebo
Participants in this arm will receive placebo |
Participants in this arm will receive 42 weeks of placebo |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Heavy drinking days
Tidsramme: Randomization to Week 45
|
Number of heavy drinking days |
Randomization to Week 45
|
|
Total drinking days
Tidsramme: Randomization to Week 45
|
Total number of drinking days |
Randomization to Week 45
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Eric Bomberg, MD, University of Minnesota
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- PEDS-2026-35422
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified study data will be shared upon completion of a data use agreement
IPD-delingstidsramme
April 30, 2033 (start date) April 30, 2037 (end date)
Tilgangskriterier for IPD-deling
Interested parties should contact Dr. Bomberg to start the process of starting a data use agreement
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .